Coherus Oncology (CHRS) Change in Cash (2013 - 2026)
Coherus Oncology (CHRS) posted Change in Cash of $26.4 million for Q1 2026, up 282.13% sequentially from -$14.5 million in Q4 2025, and up 160.49% YoY from $10.1 million in Q1 2025.
Coherus Oncology (CHRS) Change in Cash (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Change in Cash for 14 years, with the latest figure at $26.4 million in Q1 2026.
- Quarterly Change in Cash rose 160.49% year-over-year to $26.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.8 million (up 118.48% YoY) and the FY2025 annual result came in at -$37.1 million, down 262.09% from the prior year.
- Change in Cash rose to $26.4 million in Q1 2026 per CHRS's latest filing, from -$14.5 million in the prior quarter.
- Over five years, Change in Cash peaked at $156.9 million in Q1 2024 and troughed at -$223.3 million in Q4 2022.
- A 5-year average of -$17.8 million and a median of -$14.5 million in 2025 frame the typical range for Change in Cash.
- The widest YoY moves for Change in Cash: up 430.96% in 2024, down 939.87% in 2024.
- Over 5 years, Change in Cash stood at -$223.3 million in 2022, then soared by 110.14% to $22.6 million in 2023, then grew by 25.03% to $28.3 million in 2024, then slumped by 151.15% to -$14.5 million in 2025, then soared by 282.13% to $26.4 million in 2026.
- According to Business Quant data, Change in Cash over the past three periods registered $26.4 million, -$14.5 million, and -$113.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn | -32.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -32.32 Mn |
| Mar 31, 2026 | 26.36 Mn |
| Dec 31, 2025 | -14.47 Mn |
| Sep 30, 2025 | -113.56 Mn |
| Jun 30, 2025 | 134.48 Mn |
| Mar 31, 2025 | -43.58 Mn |
| Dec 31, 2024 | 28.30 Mn |
| Sep 30, 2024 | -61.74 Mn |
| Jun 30, 2024 | -100.54 Mn |
| Mar 31, 2024 | 156.88 Mn |
| Dec 31, 2023 | 22.63 Mn |
| Sep 30, 2023 | 7.35 Mn |
| Jun 30, 2023 | 56.78 Mn |
| Mar 31, 2023 | -47.40 Mn |
| Dec 31, 2022 | -223.26 Mn |
| Sep 30, 2022 | 11.32 Mn |
| Jun 30, 2022 | -50.20 Mn |
| Mar 31, 2022 | -91.52 Mn |
| Dec 31, 2021 | 56.66 Mn |
| Sep 30, 2021 | 30.80 Mn |